John Tucker MBA

CEO at XyloCor Therapeutics

Greenland, New Hampshire, United States

About

CEO and board-level leader with 20+ years of experience driving growth, strategic transformation, and value creation across biotechnology and pharmaceuticals. Proven operator with a track record of IPO execution, regulatory approvals, commercial launch excellence, and successful exits exceeding $1B in value. Known for building high-performance cultures and guiding companies through inflection points in clinical, regulatory, and commercial development.

Experience

  • CEO at scPharmaceuticals
    May 2017 - Oct 2025 · 8 yrs 6 mos

    CEO & Board Member | 2017 – 2025 • Guided the company from late‑stage clinical development through commercialization, IPO, and strategic sale to MannKind. • Oversaw regulatory strategy securing first NDA approval and two label expansions. • Launched first commercial product achieving ~$100M run rate. • Raised $400M+ including $102M IPO and multiple debt/royalty financings. • Reduced COGs by 45% through manufacturing and supply‑chain optimization.

  • CEO at Alcresta
    Apr 2014 - Jul 2016 · 2 yrs 4 mos

    CEO & Board Member | 2014 – 2016 • Repositioned company around lead indication and built integrated clinical, regulatory, and commercial framework. • Secured FDA approval for first product within 19 months. • Closed $55M Series C financing with top‑tier investors leading to successful exit

  • Chief Commercial Officer at Incline Therapeutics, Inc
    2012 - Apr 2014 · 2 yrs 4 mos

    Developed overall commercial and medical affairs strategy and direction for VC backed company. Designed and implemented commercial structure, budgets, forecasts and market entry strategy. Developed corporate commercial strategy and value story for IONSYS in US and the EU resulting in $390 million sale to The Medicines Company

  • VP, Commercial Operations at AMAG Pharmaceuticals
    Jan 2012 - Jun 2012 · 6 mos

    Recruited to turnaround the US business as the company progressed through a strategic review and sale process. Responsible for all sales, marketing and sales operations in support of Feraheme. Designed and implemented new incentive compensation plan, sales force targeting plan and marketing plan that drove record product sales. Responsible for commercial representation in all potential M&A presentations and due diligence.

  • President at Basilea Pharmaceutica Ltd
    Jun 2007 - Dec 2011 · 4 yrs 7 mos

    Recruited to establish Basilea commercial presence in US. Responsible for establishing development, regulatory and commercial strategy in preparation for first product launch. Designed and implemented financial structure and manpower requirements for US organization. Global Business Development lead for commercial partnerships.